通过质谱法对抗体-药物偶联物进行表征：进展与未来趋势
Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends.
作者信息
Huang Richard Y-C, Chen Guodong
机构信息
Bioanalytical and Discovery Analytical Sciences, Research and Development, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, USA.
Bioanalytical and Discovery Analytical Sciences, Research and Development, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, USA.
出版信息
Drug Discov Today. 2016 May;21(5):850-5. doi: 10.1016/j.drudis.2016.04.004. Epub 2016 Apr 11.
Antibody-drug conjugates (ADCs) are emerging modalities in the pharmaceutical industry. The unique target-specific binding of antibody allows targeted delivery of cytotoxic small molecules to cancer cells, and thus expands the therapeutic window. However, in-depth characterization of ADCs is complex because it involves the characterization of antibody, conjugated molecules and antibody conjugates as a whole. In this review, we describe the practical use of mass spectrometry for ADC characterization including qualitative and quantitative analysis. Technical advances, limitations and future trends will also be discussed.
抗体药物偶联物（ADCs）是制药行业中新兴的药物形式。抗体独特的靶向特异性结合能够将细胞毒性小分子靶向递送至癌细胞，从而扩大治疗窗口。然而，对ADCs进行深入表征很复杂，因为这涉及到对抗体、偶联分子以及整个抗体偶联物的表征。在本综述中，我们描述了质谱在ADCs表征中的实际应用，包括定性和定量分析。还将讨论技术进展、局限性和未来趋势。
Zotero 插件